CZ20012373A3 - Derivát azepinindolu, jeho pouľití a farmaceutický prostředek, který ho obsahuje - Google Patents

Derivát azepinindolu, jeho pouľití a farmaceutický prostředek, který ho obsahuje Download PDF

Info

Publication number
CZ20012373A3
CZ20012373A3 CZ20012373A CZ20012373A CZ20012373A3 CZ 20012373 A3 CZ20012373 A3 CZ 20012373A3 CZ 20012373 A CZ20012373 A CZ 20012373A CZ 20012373 A CZ20012373 A CZ 20012373A CZ 20012373 A3 CZ20012373 A3 CZ 20012373A3
Authority
CZ
Czechia
Prior art keywords
alkyl
carbon atoms
group
formula
compounds
Prior art date
Application number
CZ20012373A
Other languages
Czech (cs)
English (en)
Inventor
Wilfried Lubisch
Michael Kock
Thomas Höger
Sabine Schult
Roland Grandel
Reinhold MÜLLER
Original Assignee
Basf Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19946289A external-priority patent/DE19946289A1/de
Priority claimed from DE10039610A external-priority patent/DE10039610A1/de
Application filed by Basf Aktiengesellschaft filed Critical Basf Aktiengesellschaft
Publication of CZ20012373A3 publication Critical patent/CZ20012373A3/cs

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CZ20012373A 1999-09-28 2000-09-15 Derivát azepinindolu, jeho pouľití a farmaceutický prostředek, který ho obsahuje CZ20012373A3 (cs)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19946289A DE19946289A1 (de) 1999-09-28 1999-09-28 Benzodiazepin-Derivate, deren Herstellung und Anwendung
DE10039610A DE10039610A1 (de) 2000-08-09 2000-08-09 Azepinoindol-Derivate, deren Herstellung und Anwendung

Publications (1)

Publication Number Publication Date
CZ20012373A3 true CZ20012373A3 (cs) 2002-05-15

Family

ID=26006691

Family Applications (1)

Application Number Title Priority Date Filing Date
CZ20012373A CZ20012373A3 (cs) 1999-09-28 2000-09-15 Derivát azepinindolu, jeho pouľití a farmaceutický prostředek, který ho obsahuje

Country Status (17)

Country Link
EP (1) EP1183259A2 (tr)
JP (1) JP2003510328A (tr)
KR (1) KR20010087401A (tr)
CN (1) CN1374961A (tr)
AU (1) AU1271201A (tr)
BG (1) BG105650A (tr)
BR (1) BR0007174A (tr)
CA (1) CA2352194A1 (tr)
CZ (1) CZ20012373A3 (tr)
HK (1) HK1048999A1 (tr)
HU (1) HUP0104917A3 (tr)
IL (1) IL143349A0 (tr)
NO (1) NO20012567L (tr)
PL (1) PL347885A1 (tr)
SK (1) SK8842001A3 (tr)
TR (1) TR200101499T1 (tr)
WO (1) WO2001023390A2 (tr)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL210415B1 (pl) 1999-01-11 2012-01-31 Agouron Pharma Pochodne indolu, środek farmaceutyczny i zastosowanie pochodnych indolu
US7151102B2 (en) 2000-10-30 2006-12-19 Kudos Pharmaceuticals Limited Phthalazinone derivatives
CA2430363C (en) 2000-12-01 2010-04-13 Guilford Pharmaceuticals Inc. Compounds and their uses
US7026311B2 (en) * 2002-01-10 2006-04-11 Abbott Gmbh & Co., Kg Dibenzodiazepine derivatives, their preparation and use
DE60335359D1 (de) 2002-04-30 2011-01-27 Kudos Pharm Ltd Phthalazinonderivate
EP1527183B1 (de) 2002-07-26 2008-08-20 BASF Plant Science GmbH Neue selektionsverfahren
GB0305681D0 (en) 2003-03-12 2003-04-16 Kudos Pharm Ltd Phthalazinone derivatives
US7449464B2 (en) 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
US7223759B2 (en) 2003-09-15 2007-05-29 Anadys Pharmaceuticals, Inc. Antibacterial 3,5-diaminopiperidine-substituted aromatic and heteroaromatic compounds
DK2305221T3 (en) 2003-12-01 2015-08-24 Kudos Pharm Ltd DNA damage repair inhibitors for the treatment of cancer
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7868037B2 (en) 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
JP2008506702A (ja) 2004-07-14 2008-03-06 ピーティーシー セラピューティクス，インコーポレーテッド Ｃ型肝炎を治療するための方法
US7645881B2 (en) 2004-07-22 2010-01-12 Ptc Therapeutics, Inc. Methods for treating hepatitis C
ATE541043T1 (de) 2005-03-08 2012-01-15 Basf Plant Science Gmbh Expressionsverstärkende intron-sequenz
US7662824B2 (en) 2005-03-18 2010-02-16 Janssen Pharmaceutica Nv Acylhydrazones as kinase modulators
GB0521373D0 (en) 2005-10-20 2005-11-30 Kudos Pharm Ltd Pthalazinone derivatives
UY30639A1 (es) 2006-10-17 2008-05-31 Kudos Pharm Ltd Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones
CN101809017A (zh) 2007-09-14 2010-08-18 阿斯利康(瑞典)有限公司 酞嗪酮衍生物
AR070221A1 (es) 2008-01-23 2010-03-25 Astrazeneca Ab Derivados de ftalazinona inhibidores de polimerasas, composiciones farmaceuticas que los contienen y usos de los mismos para prevenir y/o tratar tumores cancerigenos,lesiones isquemicas y otras enfermedades asociadas.
GB0804755D0 (en) * 2008-03-14 2008-04-16 Angeletti P Ist Richerche Bio Therapeutic compounds
EP2346495B2 (en) 2008-10-07 2023-05-24 Kudos Pharmaceuticals Limited Pharmaceutical formulation 514
WO2011058367A2 (en) 2009-11-13 2011-05-19 Astrazeneca Ab Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor
CA2781835A1 (en) 2009-11-27 2011-06-03 Basf Plant Science Company Gmbh Chimeric endonucleases and uses thereof
CA2782014C (en) 2009-11-27 2021-08-31 Basf Plant Science Company Gmbh Optimized endonucleases and uses thereof
BR112012012747A2 (pt) 2009-11-27 2015-09-29 Basf Plant Science Co Gmbh "endonuclease quimérica, polinucleotídeo isolado, cassete de expressão, vetor célula hospedeira ou organismo não humano, método para fornecer a endonuclease quimérica, método para a recombinação homóloga dos polinucleotídeos e método para mutação direcionada de polinucleotídeos"
CN103096893B (zh) 2010-06-04 2016-05-04 阿尔巴尼分子研究公司 甘氨酸转运体-1抑制剂、其制备方法及其用途
KR101896567B1 (ko) 2015-07-23 2018-09-07 인스티튜트 큐리 암 치료를 위한 디베이트 분자와 parp 억제제의 병용 용도
GB201519573D0 (en) 2015-11-05 2015-12-23 King S College London Combination
WO2018162439A1 (en) 2017-03-08 2018-09-13 Onxeo New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule
WO2018197461A1 (en) 2017-04-28 2018-11-01 Akribes Biomedical Gmbh A parp inhibitor in combination with a glucocorticoid and/or ascorbic acid and/or a protein growth factor for the treatment of impaired wound healing
US11161865B2 (en) * 2017-05-24 2021-11-02 The Trustees Of The University Of Pennsylvania Radiolabeled and fluorescent PARP inhibitors for imaging and radiotherapy
CA3092779A1 (en) 2018-03-13 2019-09-19 Onxeo A dbait molecule against acquired resistance in the treatment of cancer
US11034669B2 (en) 2018-11-30 2021-06-15 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
EP3919495A4 (en) * 2019-02-02 2022-10-19 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. INDOLO-HEPTAMYL-OXIME ANALOG AS A PARP INHIBITOR
CN114072410B (zh) * 2019-08-01 2023-08-01 正大天晴药业集团股份有限公司 作为parp抑制剂吲哚并七元酰肟化合物
GB201913030D0 (en) 2019-09-10 2019-10-23 Francis Crick Institute Ltd Treatment of hr deficient cancer
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN115698019A (zh) * 2020-07-31 2023-02-03 正大天晴药业集团股份有限公司 用作parp抑制剂的吲哚并七元酰肟类似物的结晶及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999011644A1 (en) * 1997-09-03 1999-03-11 Guilford Pharmaceuticals Inc. Di-n-heterocyclic compounds, methods, and compositions for inhibiting parp activity
PL210415B1 (pl) * 1999-01-11 2012-01-31 Agouron Pharma Pochodne indolu, środek farmaceutyczny i zastosowanie pochodnych indolu
ECSP003637A (es) * 1999-08-31 2002-03-25 Agouron Pharma Inhibidores triciclicos de poli (adp-ribosa) polimerasas

Also Published As

Publication number Publication date
WO2001023390A3 (de) 2001-12-27
HK1048999A1 (zh) 2003-04-25
CN1374961A (zh) 2002-10-16
HUP0104917A3 (en) 2002-12-28
WO2001023390A2 (de) 2001-04-05
BR0007174A (pt) 2001-09-04
CA2352194A1 (en) 2001-04-05
SK8842001A3 (en) 2002-01-07
AU1271201A (en) 2001-04-30
JP2003510328A (ja) 2003-03-18
BG105650A (en) 2002-02-28
PL347885A1 (en) 2002-04-22
TR200101499T1 (tr) 2002-09-23
EP1183259A2 (de) 2002-03-06
NO20012567D0 (no) 2001-05-25
KR20010087401A (ko) 2001-09-15
NO20012567L (no) 2001-06-25
HUP0104917A2 (hu) 2002-04-29
IL143349A0 (en) 2002-04-21

Similar Documents

Publication Publication Date Title
CZ20012373A3 (cs) Derivát azepinindolu, jeho pouľití a farmaceutický prostředek, který ho obsahuje
US7087637B2 (en) Substituted indoles which are PARP inhibitors
US8318720B2 (en) Acrylamide derivatives as Fab I inhibitors
US9029392B2 (en) Quinoline derivatives as kinase inhibitors
JP5042888B2 (ja) Ｊａｋおよび他のプロテインキナーゼの阻害剤として有用なアザインドール
US20080261975A1 (en) Tec Kinase Inhibitors
SK286676B6 (sk) Použitie ftalazínových derivátov
PL196367B1 (pl) Podstawione benzimidazole, ich zastosowanie jako inhibitorów PARP oraz środek leczniczy
CZ20011724A3 (cs) Použití derivátu 2-fenylbenzimidazolu a 2-fenylindolu pro výrobu drog
CZ20013775A3 (cs) Derivát benzimidazolu substituovaný cykloalkylovou skupinou, způsob jeho přípravy a jeho pouľití
KR20020031602A (ko) 벤조디아제핀 유도체, 그의 제조 방법 및 용도
US10919869B2 (en) Thiazole derivative and applications
AU2002247059B2 (en) Method of treating inflammatory and immune diseases using inhibitors of IkappaB kinase (IKK)
CZ126899A3 (cs) Deriváty kyseliny piperidinketokarbonové, jejich použití a léčebný přípravek
AU2002211827B2 (en) Amino-substituted tetracyclic compounds useful as anti-inflammatory agents and pharmaceutical compositions comprising same
US20060183908A1 (en) Heterocyclic compounds, methods of making them and their use in therapy
CA2388729A1 (en) Imidazopyridine derivatives as phosphodiesterase vii inhibitors
US7026311B2 (en) Dibenzodiazepine derivatives, their preparation and use
JP2015028010A (ja) フルオレン−アミド化合物およびその医薬用途
KR100345187B1 (ko) 트롬복산a2-개재된질환의예방및치료제
KR101048377B1 (ko) 2,4-비스(트리플루오로에톡시)피리딘 화합물 및 이를함유하는 의약.
MXPA01005199A (en) Azepinoindole derivatives, the production and use thereof
CN116063326A (zh) 作为蛋白激酶调节剂的含氨基大环化合物